



## PRESS RELEASE

Berlin, 18 February 2016

### ● **Organobalance acquires Lonza Probiotic Licence**

Natural agent against *Helicobacter* has potential to replace antibiotics

With immediate effect, Organobalance GmbH will take over the marketing of a probiotic agent against *Helicobacter pylori* developed by the company. This active ingredient had previously been marketed by the Swiss company Lonza under the trade name Pylopass™. Lonza returned the licence to Organobalance after restructuring its product portfolio. “We are very happy to be able to acquire from our partner Lonza this successfully established brand and will continue its global marketing”, stated Prof. Dr. Christine Lang, the company’s managing director.

Pylopass™ is based on *Lactobacillus reuteri* DSM17648, a Lactobacillus strain. Organobalance had demonstrated the strain’s ability to bind with high specificity *Helicobacter* microbes and be flushed out of the stomach naturally. During this study, a total of some 700 lactobacilli from the Organobalance GmbH’s strain collection were tested. The process of treating *Helicobacter pylori* with a Lactobacillus has been patented.

“Pylopass has a unique effect on the carcinogenic stomach bacterium *Helicobacter pylori*”, emphasises Christine Lang. “In contrast to conventional treatment with antibiotics, patients can be treated more conservatively while protecting the natural microflora.”

By some estimates, more than half the global population harbours the *Helicobacter* pathogen, but not all of those infected suffer from typical symptoms, painful irritations, or cancer. Current conventional treatment consists of administering several antibiotics. “It is our goal to move away from antibiotics because they not only destroy harmful, but also beneficial bacteria”, Prof. Lang explained when publishing the study (<http://link.springer.com/article/10.1007/s12602-014-9181-3>).

#### **About Organobalance GmbH:**

ORGANOBALANCE is a biotechnology research and development company. Founded in 2001, the firm develops and sells products based on probiotic bacteria cultures and yeast production strains for use in industrial biotechnology. The company owns a unique strain collection of yeast and lactobacillus cultures, some of which date back to the 1920s. At its offices in Berlin and Flensburg, some 35 employees work for multinational clients from the food, cosmetics, feed, agriculture and pharmaceutical industries. Christine Lang, the company’s Managing Director, is also a Professor of Microbiology and Molecular Genetics at the TU Berlin and have already received several business awards.



**For further information:**  
ORGANO BALANCE GmbH  
Gustav-Meyer-Allee 25  
13355 Berlin  
Fon (030) 46307 200  
Fax (030) 46307 210  
[www.organobalance.de](http://www.organobalance.de)